GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated July 1, 2024, serves as a notification to the market regarding the company's issued share capital and total voting rights as of June 30, 2024. The filing is made in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely updates the share count figures used for regulatory notification thresholds.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to inform shareholders of the denominator for calculating notification requirements under FCA rules.
Key Facts for Investor Verification
- Issued Share Capital: As of June 30, 2024, GSK Plc had 4,314,215,315 Ordinary Shares of 31.25 pence each.
- Treasury Shares: 169,171,155 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,145,044,160.
- Regulatory Use: Shareholders must use the 4,145,044,160 figure as the denominator to determine if they are required to notify their interest or changes in interest under FCA rules.
- Contact: Notifications should be sent to company.secretary@gsk.com.